Orphazyme A/S (ORPHA.CO)

DKK 1120.0

(-2.61%)

Net Debt Summary of Orphazyme A/S

Orphazyme A/S's latest annual net debt in 2023 was -11.26 Million DKK , up 71.04% from previous year.
Orphazyme A/S's latest quarterly net debt in 2024 Q2 was -13.97 Million DKK , down 0.0% from previous quarter.
Orphazyme A/S reported annual net debt of -38.91 Million DKK in 2022, up 37.52% from previous year.
Orphazyme A/S reported annual net debt of -62.28 Million DKK in 2021, up 90.51% from previous year.
Orphazyme A/S reported quarterly net debt of -13.97 Million DKK for 2024 Q1, down -24.0% from previous quarter.
Orphazyme A/S reported quarterly net debt of -30.34 Million DKK for 2023 Q2, down 0.0% from previous quarter.

Annual Net Debt Chart of Orphazyme A/S (2023 - 2013)

Historical Annual Net Debt of Orphazyme A/S (2023 - 2013)

Year	Net Debt	Net Debt Growth
2023	-11.26 Million DKK	71.04%
2022	-38.91 Million DKK	37.52%
2021	-62.28 Million DKK	90.51%
2020	-656.21 Million DKK	-1311.82%
2019	-46.48 Million DKK	88.22%
2018	-394.7 Million DKK	37.52%
2017	-631.73 Million DKK	-4302.64%
2016	-14.34 Million DKK	78.83%
2015	-67.77 Million DKK	13.02%
2014	-77.91 Million DKK	-202.81%
2013	-25.73 Million DKK	0.0%

Year	Net Debt	Net Debt Growth
2024 Q2	-13.97 Million DKK	0.0%
2024 Q1	-13.97 Million DKK	-24.0%
2023 Q2	-30.34 Million DKK	0.0%
2023 Q3	-11.26 Million DKK	62.86%
2023 FY	-11.26 Million DKK	71.04%
2023 Q1	-30.34 Million DKK	28.55%
2023 Q4	-11.26 Million DKK	0.0%
2022 Q4	-42.46 Million DKK	-9.11%
2022 Q3	-38.91 Million DKK	21.43%
2022 FY	-38.91 Million DKK	37.52%
2022 Q2	-49.53 Million DKK	0.0%
2022 Q1	-49.53 Million DKK	20.48%
2021 Q3	-64.86 Million DKK	76.46%
2021 FY	-62.28 Million DKK	90.51%
2021 Q1	-277.64 Million DKK	57.69%
2021 Q2	-275.59 Million DKK	0.74%
2021 Q4	-62.28 Million DKK	3.97%
2020 Q2	-529.5 Million DKK	0.6%
2020 FY	-656.21 Million DKK	-1311.82%
2020 Q4	-656.21 Million DKK	0.55%
2020 Q3	-659.87 Million DKK	-24.62%
2020 Q1	-532.69 Million DKK	-1046.06%
2019 FY	-46.48 Million DKK	88.22%
2019 Q1	-216.01 Million DKK	45.27%
2019 Q3	-49.35 Million DKK	77.15%
2019 Q4	-46.48 Million DKK	5.83%
2019 Q2	-216.01 Million DKK	0.0%
2018 Q4	-394.7 Million DKK	0.0%
2018 FY	-394.7 Million DKK	37.52%
2018 Q1	-513.37 Million DKK	18.74%
2018 Q2	-513.37 Million DKK	0.0%
2018 Q3	-394.7 Million DKK	23.11%
2017 Q2	-33.58 Million DKK	0.0%
2017 FY	-631.73 Million DKK	-4302.64%
2017 Q4	-631.73 Million DKK	0.0%
2017 Q3	-631.73 Million DKK	-1780.78%
2017 Q1	-33.58 Million DKK	-134.09%
2016 Q3	-14.34 Million DKK	0.0%
2016 Q4	-14.34 Million DKK	0.0%
2016 Q1	68.01 Million DKK	0.0%
2016 FY	-14.34 Million DKK	78.83%
2015 FY	-67.77 Million DKK	13.02%
2014 FY	-77.91 Million DKK	-202.81%
2013 FY	-25.73 Million DKK	0.0%

Peer Net Debt Comparison of Orphazyme A/S

Name	Net Debt	Net Debt Difference
ALK-Abelló A/S	291 Million DKK	103.873%
Bavarian Nordic A/S	-1.33 Billion DKK	99.154%
Genmab A/S	-14.09 Billion DKK	99.92%
Gubra A/S	18.03 Million DKK	162.474%
Novo Nordisk A/S	12.61 Billion DKK	100.089%
Pharma Equity Group A/S	25.99 Million DKK	143.359%
Zealand Pharma A/S	-249.03 Million DKK	95.475%